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ABSTRACT
The increased stiffness of a tumor triggers a multitude of responses that aid cancer cell dissemination.
Stiffness-induced expression of CCN1 mediates autocrine signaling in the endothelium to upregulate
N-Cadherin levels. This permits more stable interactions with cancer cells and increases their ability to




Metastasis is the leading cause for cancer related deaths. The
vascular endothelial cells (ECs) are key players in this process
by providing a major route for cancer cells to escape the
primary tumor and metastasize to distant sites. Cancer cell
intravasation is facilitated by leaky tumor vessels and by the
expression of cellular adhesion proteins on the cancer and
endothelial cells. However, the effect of the tumor microenvi-
ronment on the ECs and the impact this has on metastasis is
not well deﬁned.
The extracellular matrix (ECM) is heavily remodeled during
tumor development and is dynamic both in its composition
and structural properties. Alterations in the ECM during tumor
progression often lead to increased tumor stiffness, promoting
primary tumor growth and metastasis by directly affecting can-
cer cells through the activation of integrin signaling.1 Increased
matrix stiffness also helps initiate and maintain the activated
cancer associated ﬁbroblast phenotype, which in turn promotes
cancer dissemination.2 The oncogene transcriptional coactiva-
tor YAP1 is a stiffness sensitive transcription factor, whose clas-
sical targets include the protein CYR61 (also known as CCN1),
which is a secreted matrix-bound protein upregulated during
inﬂammation, wound healing, tissue repair and tumorigenesis.
CCN1 is crucial in physiological angiogenesis and vascular
development and also possesses pro-tumorigenic and pro-
metastatic roles as a ligand itself or by binding growth factors,
metalloproteases (MMPs) and cytokines to modulate their sig-
naling.3 CCN1 acts on cancer cells, ﬁbroblasts, ECs and
immune cells as a non-RGD-containing ligand of integrins
avb3, a6b1, avb5, aMb2 and aIIbb33,4. In ECs the dominant
receptor is avb3, mediating migration, survival and tubule for-
mation.5 The context speciﬁc signaling of CCN1 is likely due to
its modular domain structure, enabling multiple integrin and
co-receptor engagement at once, triggering a unique down-
stream signaling.3,4
Tumor stiffness: A sticky situation
To assess how tumor matrix stiffness affects ECs, we cultured
primary human umbilical vein endothelial cells (HUVECs
referred to as ECs) on polyacrylamide gels representing physio-
logical (400 Pa) or tumor stiffness (22000 Pa).1 Mass spectrom-
etry-based proteomic analyses revealed approximately 250 of
the 5,400 proteins quantiﬁed were regulated with stiffness
(Datasets are publically available6). Several transmembrane cell
adhesion proteins were upregulated with stiffness, in particular
N-Cadherin. Unlike VE-Cadherin at cell-cell contacts, N-Cad-
herin is dispersed over the cell surface, mediating contacts with
other cell types such as pericytes. In a tumor context, epithelial
to mesenchymal transition (EMT) typically yields metastatic
cancer cells expressing elevated N-Cadherin, which plays a key
role in the process of transendothelial migration (TEM) during
intravasation and extravasation.7 We hypothesized that the
alteration in vascular N-Cadherin may affect the ability of can-
cer cells to cross the endothelial barrier.
CCN1 was signiﬁcantly upregulated at high stiffness in cul-
tured ECs and in an orthotopically transplanted breast cancer
model. CCN1 was also found to be upstream of stiffness-
induced N-Cadherin expression, which is partly dependent on
b-catenin activity.
We recapitulated the initial stage of metastasis in vitro and
measured the ability of N-cadherin expressing cancer cells to
stably adhere to the endothelium and to transmigrate through
a microvascular endothelial monolayer. ECs expressing CCN1
at high stiffness increased the binding of cancer cells via N-
Cadherin interactions, and CCN1 loss prevented cancer cell
binding and TEM. Furthermore, intravital imaging analysis of
the interaction between ﬂuorescently labelled B16F10 cancer
cells and the vasculature demonstrated that loss of endothelial
CCN1 reduces cancer cell attachment to the endothelium,
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whilst increasing motility along the blood vessels. Additionally,
injection of a soluble Cre protein intravenously into Cyr61loxP/
loxP mice induced a partial vascular recombination. Together
with the B16F10 subcutaneous syngeneic tumor model, Cyr61
knockout resulted in fewer lung metastases and detectable cir-
culating cancer cells, without affecting primary tumor growth,
vascularity, hypoxia or pericyte coverage. Conversely, incidence
of lung metastases when B16F10 cells were intravenously
injected was not affected in an EC-speciﬁc Cyr61 knockout
mouse model.
This data enabled us to draw a model through which endo-
thelial CCN1 controls cancer cell metastasis. The desmoplastic
reaction that accompanies tumor aggressiveness induces
increased levels of endothelial CCN1, which, in turn, upregu-
lates the N-Cadherin available at the surface of the blood ves-
sels. Endothelial N-Cadherin facilitates homophilic heterotypic
interactions with aggressive cancer cells that have undergone
EMT thus facilitating their intravasation in the blood stream to
form distant metastasis (Figure 1).
Other cell-cell adhesion proteins were also increased with
matrix stiffness in the ECs, some of which have been implicated
in EC-leukocyte interactions. For example CD166 antigen (also
known as ALCAM) and poliovirus receptor, which are both
crucial in TEM of monocytes.8,9 Moreover, high levels of
ALCAM in tumor ECs mediate intratumoral inﬁltration of T-
regulatory cells.10 One could speculate that increased stiffness
could affect immune cell inﬁltration into the tumor and thus
impact tumor progression.
This recent work6 was the ﬁrst to establish that tumor stiff-
ness could inﬂuence the endothelium in such a way to aid can-
cer metastasis. Since CCN1 is extracellular and binds multiple
cell speciﬁc integrins, it is conceivable that therapeutically tar-
geting CCN1 would also impact other cell types with unknown
consequences. Further studies are required to fully understand
this interaction and unlock to the potential for therapeutic
intervention.
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Figure 1. Role of endothelial CCN1 in metastasis. We propose that tumor stiffness induces protein CYR61 (indicated as CCN1) expression, which mediates b-catenin sig-
naling and N-Cadherin expression in the endothelium. N-Cadherin engagement with the cancer cells facilitates their adhesion and transendothelial migration into the
bloodstream subsequently increasing the likelihood to generate metastasis. ECM D extracellular matrix. EC D endothelial cell. Images adapted from Servier Medical Art
http://smart.servier.com/.
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